Is DMT in clinical trials?

Yes. This page indexes 52 registered trials of DMT, 5-MeO-DMT, and ayahuasca — most investigating depression and other mental-health conditions, at institutions including Imperial College London and several biotech sponsors.

Can I join a DMT study?

Trial eligibility, locations, and recruitment status are listed on each trial's official ClinicalTrials.gov page (linked here). The DMT Atlas is an information archive and cannot enroll anyone or provide access to any substance.

RESEARCH · THE DMT ATLAS

DMT Clinical Trials

Every registered clinical trial of DMT, 5-MeO-DMT, and ayahuasca we could find — 52 studies from ClinicalTrials.gov and other registries, newest first. Status, phase, condition, and sponsor for each, linked to the official registry entry.

Showing 52 of 52

Trial	Phase	Status	Condition	Sponsor	Start
Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants ↗	Phase 1	Recruiting	5-methoxy-dimethyltryptamine (5-MeO-DMT)	University Hospital, Basel, Switzerland	2026-03
Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects ↗	Phase 1	Not yet recruiting	Healthy Adult	GH Research Ireland Limited	2026-04
Inhaled DMT for Major Depressive Disorder ↗	Phase 2	Recruiting	MDD, Major Depressive Disorder (MDD), Major Depression	Universidade Federal do Rio Grande do Norte	2026-08
Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) ↗	Phase 1	Not yet recruiting	Healthy Participants Study	Jon Dean	2026-09
Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants ↗	Phase 1	Completed	Healthy	University Hospital, Basel, Switzerland	2025-01
Investigation of Psychedelic Effects in Psychoactive Substances ↗	Phase 1	Recruiting	Psychedelic Effects in Healthy Volunteers	Johns Hopkins University	2025-02
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans ↗	Phase 1	Recruiting	Major Depression Disorder, Depression	Deepak C. D'Souza	2025-03
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) ↗	Phase 1	Recruiting	Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use	Yale University	2025-08
Antidepressant Response of DMT Masked With Propofol ↗	N/a	Recruiting	Major Depressive Disorder, Psychedelic Experiences	University Hospital, Basel, Switzerland	2025-08
Trifecta Research Study ↗	Phase 2	Withdrawn	PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma	Johns Hopkins University	2025-09
Ayahuasca, Esketamine and PTSD ↗	Phase 2	Recruiting	Posttraumatic Stress Disorder (PTSD)	University of Sao Paulo	2025-12
Ayahuasca, Esketamine and Premenstrual Symptoms ↗	N/a	Recruiting	Healthy Women Volunteers	University of Sao Paulo	2025-12
Ayahuasca, Esketamine and Body Image Perception ↗	N/a	Recruiting	Healthy Women Volunteers	University of Sao Paulo	2025-12
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach ↗	Phase 1	Completed	Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine	Insel Gruppe AG, University Hospital Bern	2024-01
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) ↗	Phase 2	Active not recruiting	Generalized Anxiety Disorder	Cybin IRL Limited	2024-05
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) ↗	Phase 1	Completed	Healthy	University Hospital, Basel, Switzerland	2024-06
Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects ↗	Phase 1	Recruiting	Healthy Volunteers	GH Research Ireland Limited	2024-08
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety ↗	Phase 1, Phase 2	Completed	Healthy Volunteers	Biomind Labs Inc.	2024-10
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics ↗	N/a	Terminated	OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)	Yale University	2024-12
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI ↗	Phase 1, Phase 2	Completed	Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder	Biomind Labs Inc.	2024-12
IM and IV SPL026 Drug Product in Healthy Participants ↗	Phase 1	Completed	Major Depressive Disorder	Small Pharma Ltd	2023-01
Single and Repeat Doses of DMT in Healthy Subjects ↗	Phase 1	Active not recruiting	Stroke	Algernon Pharmaceuticals	2023-01
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression ↗	Phase 2	Recruiting	Treatment Resistant Depression	Beckley Psytech Limited	2023-02
Mindfulness and Psychedelics ↗	Early Phase 1	Completed	Healthy Participants	Milan Scheidegger	2023-02
Phase 2 Clinical Trial of GH001 in Postpartum Depression ↗	Phase 2	Terminated	Postpartum Depression, Postnatal Depression	GH Research Ireland Limited	2023-03
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder ↗	Phase 2	Terminated	Bipolar II Disorder	GH Research Ireland Limited	2023-04
Safety and Tolerability of DMT in Healthy Adults ↗	Phase 1	Completed	Safety Issues, Healthy Volunteers	Universidade Federal do Rio Grande do Norte	2023-04
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects ↗	Phase 1	Completed	Healthy	Reconnect Labs	2023-05
A Trial of GH001 in Patients With Treatment-resistant Depression ↗	Phase 2	Completed	Treatment-resistant Depression	GH Research Ireland Limited	2023-05
An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder ↗	Phase 2	Completed	Alcohol Use Disorder	Beckley Psytech Limited	2023-05
BPL-003 Efficacy and Safety in Treatment Resistant Depression ↗	Phase 2	Completed	Treatment Resistant Depression	Beckley Psytech Limited	2023-09
Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults ↗	Phase 1	Unknown	Major Depression, Post Traumatic Stress Disorder	Advanced Integrative Medical Science Institute	2023-10
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression ↗	Phase 2	Completed	Depressive Disorder, Depression, Unipolar	Universidade Federal do Rio Grande do Norte	2023-10
Single Ascending Dose Study With BPL-003 in Healthy Subjects ↗	Phase 1	Completed	Pharmacokinetics in Healthy Adults	Beckley Psytech Limited	2022-02
Clinical Study of DMT in Healthy Adults ↗	Phase 1	Completed	Healthy Volunteers	Biomind Labs Inc.	2022-06
Trifecta Research Study ↗	N/a	Active not recruiting	PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury	Axial Therapeutic Research	2022-08
Ayahuasca and Esketamine for Major Depression ↗	Phase 2	Completed	Major Depression Severe	University of Sao Paulo	2022-10
Acute Dose-dependent Effects of DMT in Healthy Subjects ↗	Phase 1	Completed	Healthy	University Hospital, Basel, Switzerland	2022-11
SPL026 With or Without SSRIs in Participants With MDD ↗	Phase 1	Completed	Major Depressive Disorder	Small Pharma Ltd	2022-12
Safety and Pharmacokinetics of GH002 in Healthy Volunteers ↗	Phase 1	Completed	Healthy Volunteers	GH Research Ireland Limited	2022-12
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers ↗	Phase 1	Completed	Pharmacokinetics, Safety, Tolerability	Usona Institute	2022-12
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients ↗	Phase 1, Phase 2	Completed	Major Depressive Disorder	Small Pharma Ltd	2021-02
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans ↗	Phase 1	Active not recruiting	Major Depressive Disorder, Depression	Yale University	2021-03
Effects of Dimethyltryptamine in Healthy Subjects ↗	Phase 1	Completed	Healthy	University Hospital, Basel, Switzerland	2021-06
Pharmacokinetics of GH001 in Healthy Volunteers ↗	Phase 1	Completed	Healthy Volunteers	GH Research Ireland Limited	2021-06
Entheogen Resurgence ↗	N/a	Completed	Psychedelic Experiences	Vireo Health	2021-09
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects ↗	Phase 1	Completed	Pharmacokinetics in Healthy Adults	Beckley Psytech Limited	2021-09
Ayahuasca Assisted Psychotherapy for Grief ↗	Phase 2	Unknown	Bereavement	Beckley Med Foundation	2021-10
Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects ↗	Early Phase 1	Completed	Emotions, Mood, Cognitive Function 1, Social	Psychiatric University Hospital, Zurich	2020-12
Safety of GH001 in Healthy Volunteers ↗	Phase 1	Completed	Healthy Volunteers	GH Research Ireland Limited	2019-03
Clinical Study of GH001 in Depression ↗	Phase 1, Phase 2	Completed	Treatment Resistant Depression, Major Depressive Disorder, Depression	GH Research Ireland Limited	2019-11
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression ↗	Phase 1, Phase 2	Completed	Major Depression	Universidade Federal do Rio Grande do Norte	2014-02

✦Preprints

Recent non-peer-reviewed preprints (bioRxiv/medRxiv/PsyArXiv). Treat as provisional.

Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders ↗

H, e, n · Preprints.org · 2026

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) ↗

T, a, b · PsyArXiv · 2025

Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study ↗

E, g, g · Research Square · 2025

5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood—a retrospective case study ↗

T, u, r · PsyArXiv · 2024

Distinct Modulatory Effects on Affective Biases by Different Serotonergic Psychedelics and MDMA in Male Rats: Possible Implications for Antidepressant Effects ↗

H, i, n · bioRxiv · 2026

Speech markers of psychedelic-induced psychological change ↗

K, u, c · bioRxiv · 2025

Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N-Dimethyltryptamine and Harmine in a Meditation Retreat ↗

E, g, g · medRxiv · 2025

Gestational LSD exposure in mouse rapidly reaches embryonic CSF and is associated with altered choroid plexus signaling, cerebral cortical development, and offspring behavior ↗

C, o, u · bioRxiv · 2025

Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice ↗

N, o, g · Research Square · 2023

The Entropy–Content Paradox in Minimal Phenomenal Experience ↗

M, a, g · PsyArXiv · 2025

Beliefs in and experiences of sorcery, black magic and brujería among psychedelic users: a quantitative and qualitative survey ↗

E, v, a · PsyArXiv · 2026

The effect of psychedelics on associative learning: a systematic review ↗

C, a, u · bioRxiv · 2025

5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats ↗

S, o, u · bioRxiv · 2023

Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample ↗

P, e, t · PsyArXiv · 2025

In Silico Characterization of Desmodium gangeticum Compounds as Dual Modulators of MAO-B and 5- HT2A in Parkinson’s Disease: An Integrated Approach Combining Molecular Docking, ADMET Profiling, MM-GBSA, QSAR Modeling, and Molecular Dynamics Simulation ↗

A, k, i · Research Square · 2026

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT ↗

T, a, r · bioRxiv · 2026

Reorganization of Human Brain Waves Across Diverse States of Consciousness ↗

F, o, t · bioRxiv · 2026

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality ↗

W, i, e · Research Square · 2026

LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-being: A Prospective, Naturalistic Study ↗

L, o, w · PsyArXiv · 2025

Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks — Including Life Between Lives and Transpersonal Hypnotherapy ↗

G, a, l · Preprints.org · 2026

SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment ↗

I, s, h · ScienceOpen Preprints · 2026

Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults ↗

C, a, r · Research Square · 2026

Inhaled N,N-Dimethyltryptamine Diminishes Connectivity between the Ventral Tegmental Area and the Nucleus Accumbens : relevance to pathologies of mesolimbic and mesocortical pathways ↗

L, i, m · Research Square · 2025

Neuroimaging in psychedelic drug development: Past, present, and future ↗

W, a, l · PsyArXiv · 2022

LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-being: A Prospective, Naturalistic Study ↗

L, o, w · PsyArXiv · 2025

LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-being: A Prospective, Naturalistic Study ↗

L, o, w · PsyArXiv · 2025

POTENCIAL TERAPÊUTICO DA AYAHUASCA COMO INTERVENÇÃO NOS TRANSTORNOS PSIQUIÁTRICOS: UMA REVISÃO SISTEMÁTICA ↗

J, u, r · SciELO Preprints · 2025

Ayahuasca Shifts Brain Dynamics Toward Higher Entropy: Persistent Elevation of Ising Temperature Correlates with Acute Subjective Effects ↗

C, a, b · bioRxiv · 2025

Ayahuasca in the treatment of bipolar disorder with psychotic features–A retrospective case study ↗

T, u, r · PsyArXiv · 2023

Psilocybin and the Evolutionary Significance of Altered Neural States: Interaction-Based Perspectives Beyond Deterrence Models ↗

R, e, b · EcoEvoRxiv · 2026

Ayahuasca – a review of historical, pharmacological, and therapeutic aspects ↗

R, u, f · PsyArXiv · 2023

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview ↗

T, a, b · PsyArXiv · 2023

Ayahuasca Mitigates Morphological Cortical Alterations in Juvenile Non-human Primates Following Chronic Stress Exposure ↗

J, ú, n · Research Square · 2025

A dual-receptor model of serotonergic psychedelics ↗

J, u, l · bioRxiv · 2024

Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic Retreat ↗

E, h, m · PsyArXiv · 2025

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community ↗

T, u, r · PsyArXiv · 2025

Increased 5-HT 2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics ↗

I, p, p · bioRxiv · 2024

The selective 5-HT 2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents ↗

J, e, n · bioRxiv · 2024

Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats ↗

K, o, l · bioRxiv · 2025

Complexity as a Potential Neurophysiological Correlate of Awe ↗

C, h, e · bioRxiv · 2025

Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users ↗

d, a, v · PsyArXiv · 2024

Effects of Ayahuasca on Ethanol-Conditioned Place Preference and ΔFosB Expression in the Nucleus Accumbens in Mice ↗

D, i, s · bioRxiv · 2024

Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N,N-dimethyltryptamine ↗

D, a, k · bioRxiv · 2017

Source: ClinicalTrials.gov API v2 and public trial registries. Registry records are informational; a listed trial is not an endorsement or an offer of treatment.